Ridgeline Discovery

Ridgeline Discovery, a Versant Ventures Discovery Engine, is a significant player in the biotechnology and IT industries. Founded in 2017, it has been instrumental in creating and operating innovative biotech companies in partnership with entrepreneurs, industry leaders, and leading academics across Europe. With an international team of over 50 highly experienced drug discovery professionals, Ridgeline has successfully built and operated several new companies, including Black Diamond Therapeutics (NASDAQ: BDTX), Bright Peak Therapeutics, and Monte Rosa Therapeutics (NASDAQ: GLUE). The company is currently focused on expanding its capabilities in Basel to support further company creation efforts in small molecules, biologics, and gene/cell therapy, with a specific emphasis on oncology and immunology. Ridgeline's collaboration with Versant Ventures has proven to be fruitful, as they continue to drive the creation and success of innovative ventures in the biotech sector. Overall, Ridgeline Discovery's strategic approach and successful track record position it as a noteworthy player in the field of biotechnology startup creation and operation, with promising prospects for future growth and influence in the industry.